AZD8330

Known as: ARRY-424704, ARRY-704, MEK Inhibitor AZD8330 
An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated… (More)

Topic mentions per year

Topic mentions per year

2013-2015
01220132015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Conventional high-grade osteosarcoma is the most common primary bone cancer with relatively high incidence in young people… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
OBJECTIVE To investigate the effect of ERK1/2 inhibitor AZD8330 on human Burkitt's lymphoma cell line Raji cells and its… (More)
Is this relevant?
2014
2014
This study was aimed to investigate the effect of MEK inhibitor AZD8330 on proliferation and apoptosis of multiple myeloma IM9… (More)
Is this relevant?
Review
2014
Review
2014
Mitogen-activated protein kinases (MAPKs) are a family of ubiquitous eukaryotic signal transduction enzymes which link… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2013
2013
OBJECTIVE This is the first clinical study of the MEK1/2 inhibitor AZD8330 (ARRY-424704). This phase I study defined the maximum… (More)
Is this relevant?
Review
2013
Review
2013
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?